Washington Health Institute

PROVIDING EXCEPTIONAL PRIMARY AND INFECTIOUS DISEASE SPECIALTY CARE SERVICES WITH A HOLISTIC PREVENTION AND CARE APPROACH.

340B FUNDING:SECTION 340B OF THE PUBLIC HEALTH SERVICE ACT (1992) REQUIRES DRUG MANUFACTURERS PARTICIPATING IN THE MEDICAID DRUG REBATE PROGRAM TO SIGN A PHARMACEUTICAL PRICING AGREEMENT (PPA) WITH THE SECRETARY OF HEALTH AND HUMAN SERVICES. THIS AGREEMENT LIMITS THE PRICE THAT MANUFACTURERSMAY CHARGE CERTAIN COVERED ENTITIES FOR COVERED OUTPATIENT DRUGS. THE 340B PROGRAM IS ADMINISTERED BY THE FEDERAL HEALTH RESOURCES AND SERVICES ADMINISTRATION (HRSA) IN THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS). UPON REGISTRATION ON 340B OPAIS (OFFICE OF PHARMACY AFFAIRS INFORMATION SYSTEM), WASHINGTON HEALTH INSTITUTE AGREES TO ABIDE BY SPECIFIC STATUTORY REQUIREMENTS AND PROHIBITIONS, AND MAY ACCESS 340B DRUGS.

CLINICAL OPERATIONS:WHI IS PROUD TO PROVIDE EXCEPTIONAL PRIMARY CARE AND INFECTIOUS DISEASES SPECIALTY CARE FOR RESIDENTS IN THE DC, MD, VIRGINIA AREA. WE OFFER CONVENIENT, ON-SITE COMPREHENSIVE TESTING AND TREATMENT FOR PATIENTS WITH SUSPECTED INFECTIOUS DISEASES, INCLUDING HIV, HEPATITIS-C, AND STIS. WE ALSO OFFER PRE-EXPOSURE PROPHYLAXIS (PREP) & POST EXPOSURE PROPHYLAXIS (PEP) TO PREVENT HIV INFECTION. WHI IS A RED CARPET (SAME-DAY) APPOINTMENTS (SAME-DAY) FOR INDIVIDUALS WHO ARE NEWLYDIAGNOSED WITH HIV OR RE-ENGAGING IN HIV CARE REGARDLESS OF ABILITY TO PAY. OUR RYAN WHITE CASE MANAGEMENT TEAM WILL WORK WITH PATIENTS TO PROACTIVELY RESOLVE ANY BARRIERS TO CARE, INCLUDING LACK OF INSURANCE.WE SERVE OVER 2,800 PATIENTS IN THE DMV AREA AND ARE RAPIDLY GROWING.ADDITIONALLY, WHI HAS A WOMEN'S HEALTH, BEHAVIORAL HEALTH, AND WEIGHT MANAGEMENT PROGRAMMING.

EIS PROGRAM:THE EARLY INTERVENTION SERVICES (EIS) TEAM AT WASHINGTON HEALTH INSTITUTE PROVIDES TARGETED OUTREACH TO RESIDENTS OF THE WASHINGTON, DC AREA AT INCREASED RISK FOR HIV INFECTION. EIS PROVIDES RAPID HIV TESTING, HIV AND SEXUAL HEALTH RISK-ASSESSMENT COUNSELING, AND SAFER-SEX MATERIALS (INCLUDING PREP, PEP, AND SAFER SEX SUPPLIES) TO THOSE SEEKING HIV-PREVENTION SERVICES. ADDITIONALLY, EIS HELPS CONNECT EXISTING WHI PATIENTS TO SERVICES AND RESOURCES AS PART OF ITS NON-MEDICAL CASE MANAGEMENT TEAM TO HELP IMPROVE THE QUALITY OF LIFE AND HOLISTIC HEALTH OF PATIENTS.

RYAN WHITE HOLISTIC CARE PROGRAM:THE RYAN WHITE HOLISTIC CARE PROGRAM ENGAGES INDIVIDUALS WITH ON-SITE SOCIAL WORKERS WHO PROVIDE COMPREHENSIVE PSYCHOSOCIAL ASSESSMENT AND WORKS WITH PATIENTS TO CREATE A UNIQUE TREATMENT PLAN TO ENHANCE THEIR HEALTH AND OVERALL WELLBEING. AS PART OF THE RYAN WHITE PROGRAM, WE OFFER MEDICAL AND NON-MEDICAL CASE MANAGEMENT SERVICES; MEDICATION ADHERENCE COUNSELING; HEALTH INSURANCE NAVIGATION; FREE OR REDUCED COST MEDICINE; REFERRALS FOR TRANSPORTATION, FOOD, FINANCIAL BENEFITS, HOUSING, EMPLOYMENT, SUBSTANCE ABUSE TREATMENT; AND MORE. THE RYAN WHITE HOLISTIC CARE PROGRAM SEEKS TO ADDRESS THE IMPORTANT NEEDS OF PATIENTS OUTSIDE OF JUST MEDICAL TREATMENT TO SUPPORT THE WELL-BEING OF THE WHOLE PERSON.THE DC COHORT GRANT:LED BY THE GEORGE WASHINGTON UNIVERSITY MILKEN INSTITUTE SCHOOL OF PUBLIC HEALTH, THE DC COHORT IS A LONGITUDINAL RESEARCH PROJECT THAT COLLECTS CLINICAL DATA FROM APPROXIMATELY 12,000 CONSENTING PEOPLE WITH HIV RECEIVING CARE AT FIFTEEN HIV CLINICS IN THE DISTRICT OF COLUMBIA. THE DC COHORT IS SPONSORED BY THE NATIONAL INSTITUTE OF HEALTH (NIH) AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID). THE PRIMARY PROJECT GOAL IS TO IMPROVE THE QUALITY OF CARE AND TREATMENT OF PEOPLE WITH HIV RECEIVING CARE AT LARGE CLINICS IN THE DISTRICT OF COLUMBIA. UNDER THE DC COHORT STUDY, THERE ARE SMALLER PROJECTS, INCLUDING THE MOLECULAR EPIDEMIOLOGY SUB-STUDY, COVID-19 SUB-STUDY, PATIENT REPORTED OUTCOMES SUB-STUDY, AND MORE. THE DC COHORT CONTRIBUTES TO THE RESEARCH OF EMERGING ISSUES IN THE PREVENTION, TREATMENT, AND LONG-TERM EFFECTS OF PEOPLE WITH HIV. THE PROJECT'S SCIENTIFIC OBJECTIVES ARE TO CONTRIBUTE TO THE KNOWLEDGE REGARDING PEOPLE WITH HIV AND THEIR TREATMENT THROUGH EVALUATING THE OUTCOMES OF HIV TREATMENT REGIMENTS OVER.CLINICAL TRIALS:THROUGH THE CLINICAL TRIALS PROGRAM, THE WASHINGTON HEALTH INSTITUTE PRIMARILY FOCUSES ON THE RESEARCH AND CURE FOR HIV BUT HAVE EXPANDED INTO STUDIES FOR OTHER DISEASES SUCH AS COVID-19, E. COLI, AND PNEUMOCOCCAL. WHI STRIVES TO BRING DIVERSITY TO CLINICAL TRIALS BY PROVIDING ACCESS TO UNDER-SERVED AND UNDER-REPRESENTED COMMUNITIES IN THE DC METRO AREA. WHI HAS PARTNERED TO CONDUCT CLINICAL RESEARCH TRIALS WITH MULTIPLE MAJOR PHARMACEUTICAL COMPANIES SUCH AS GILEADSCIENCES, VIIV, PFIZER, AMERICAN GENE TECHNOLOGIES, MEDICAGO, AND JANSSEN PHARMACEUTICALS. IT IS THE HOPE OF WHI THAT BY CONDUCTING CLINICAL RESEARCH WITH UNDER-REPRESENTED AND UNDER-SERVED COMMUNITIES, THE FACE OF MEDICINE AND PHARMACEUTICAL-BASED CARE CAN DIVERSIFY AND CHANGE FOR THE BETTER OF ALL.OTHER PROGRAMS:WHI IS FOCUSED ON OTHER KEY AREAS OF TREATMENT THAT TAKES A HOLISTIC APPROACH TO HEALTH AND PATIENT WELL-BEING. OUR PROGRAMS INCLUDE INFECTIOUS DISEASE CARE, PRIMARY CARE FOR OUR PATIENTS, TELEHEALTH VISITS, PREVENTION OF HIV AND STI'S, ON-SITE PHLEBOTOMY SERVICES, PEER SUPPORT GROUPS FOR PATIENTS, AND A WELLNESS PROGRAM.